Safe Treatment With Secukinumab in a Patient With Axial Spondyloarthritis and a History of a Leishmania donovani Infection.

Infections during treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) are some of the most frequent adverse events in patients with axial spondyloarthritis (axSpA) and with rheumatic diseases in general. We report a case of a 41-year-old White male with axSpA who developed a Leishmania donovani infection while under treatment with adalimumab (ADA).